P19963 · ALL1_OLEEU

Function

function

May be involved in recognition between pollen-stigma and pollen tube-style cells.

Miscellaneous

Replacement of several other amino acids by Ala has little or no effect on IgG binding.

GO annotations

all annotationsall molecular functionnucleotide bindingmolecular_functionnucleic acid bindingdna bindingchromatin bindingdna-binding transcription factor activityrna bindingcytoskeletal motor activitycatalytic activitynuclease activitysignaling receptor bindingstructural molecule activitytransporter activitybindingprotein bindingtranslation factor activity, rna bindinglipid bindingkinase activitytransferase activityhydrolase activityoxygen bindingenzyme regulator activitycarbohydrate bindingsignaling receptor activitytranslation regulator activitytranscription regulator activityother molecular functionall biological processcarbohydrate metabolic processgeneration of precursor metabolites and energynucleobase-containing compound metabolic processdna metabolic processtranslationlipid metabolic processtransportresponse to stresscell cyclecell communicationsignal transductioncell-cell signalingmulticellular organism developmentcircadian rhythmbiological_processmetabolic processcatabolic processbiosynthetic processresponse to light stimulusresponse to external stimulustropismresponse to biotic stimulusresponse to abiotic stimulusresponse to endogenous stimulusembryo developmentpost-embryonic developmentfruit ripeningabscissionpollinationflower developmentcellular processprogrammed cell deathphotosynthesiscellular component organizationcell growthprotein metabolic processcellular homeostasissecondary metabolic processreproductive processcell differentiationprotein modification processgrowthepigenetic regulation of gene expressionresponse to chemicalanatomical structure developmentregulation of molecular functionother biological processall cellular componentcellular_componentextracellular regioncell wallintracellular anatomical structurenucleusnuclear envelopenucleoplasmnucleoluscytoplasmmitochondrionlysosomeendosomevacuoleperoxisomeendoplasmic reticulumgolgi apparatuscytosolribosomecytoskeletonplasma membranechloroplastplastidthylakoidmembraneexternal encapsulating structureother cellular component
Cell color indicative of number of GO terms
AspectTerm
Cellular Componentendoplasmic reticulum
Cellular Componentextracellular space

Protein family/group databases

Names & Taxonomy

Protein names

  • Recommended name
    Major pollen allergen Ole e 1
  • Alternative names
    • Allergen Ole e I
  • Allergen name
    Ole e 1

Organism names

  • Taxonomic identifier
  • Strains
    • cv. Rowghani
    • Zard
    • cv. Acebuche
    • cv. Arbequina
    • cv. Bella de Espana
  • Taxonomic lineage
    Eukaryota > Viridiplantae > Streptophyta > Embryophyta > Tracheophyta > Spermatophyta > Magnoliopsida > eudicotyledons > Gunneridae > Pentapetalae > asterids > lamiids > Lamiales > Oleaceae > Oleeae > Olea

Accessions

  • Primary accession
    P19963
  • Secondary accessions
    • A5A5K8
    • A5A5K9
    • A5A5L0
    • A5A5L1
    • A5A5L2

Phenotypes & Variants

Allergenic properties

Causes an allergic reaction in human. Major allergen from olive pollen. Important in Mediterranean countries.

Features

Showing features for natural variant, mutagenesis.

TypeIDPosition(s)Description
Natural variant3in Ole e 1.0102, Ole e 1.0103 and Ole e 1.0105
Natural variant8in Ole e I.4
Mutagenesis890% loss of IgG binding.
Mutagenesis9Loss of IgG binding.
Mutagenesis10Loss of IgG binding.
Mutagenesis11Loss of IgG binding.
Natural variant12in Ole e I.4
Natural variant13in strain: cv. Zard; variant 2. In Ole e I.4
Natural variant14in strain: cv. Bella de Espana; variants 1 and 2, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine and cv. Picual; variant 1
Natural variant15in strain: cv. Picual; variant 1
Natural variant15in strain: cv. Arbequina; variants 1 and 2 and cv. Bella de Espana; variant 3
Natural variant15in strain: cv. Bella de Espana; variants 1 and 2, cv. Menara; variants 1 and 2 and cv. Picholine marocaine
Natural variant15in strain: cv. Picual; variant 3
Natural variant15in strain: cv. Loaime and cv. Picual; variant 2
Natural variant16in strain: cv. Arbequina; variant 1
Natural variant16in strain: cv. Arbequina; variant 2, cv. Bella de Espana; variant 3 and cv. Picual; variant 3
Natural variant16in strain: cv. Acebuche
Natural variant16in strain: cv. Bella de Espana; variants 1 and 2, cv. Loaime, cv. Menara; variants 1 and 2, cv. Picholine marocaine and cv. Picual; variants 1 and 2
Natural variant17in strain: cv. Rowghani; variant 3 and cv. Zard; variant 2
Natural variant17in strain: cv. Arbequina; variant 2, cv. Bella de Espana; variant 3, cv. Hojiblanca and cv. Picual; variant 3
Natural variant17in strain: cv. Acebuche
Natural variant18in strain: cv. Bella de Espana; variant 1
Natural variant18in strain: cv. Menara; variant 2
Natural variant18in strain: cv. Bella de Espana; variant 2 and cv. Picual; variant 2
Natural variant18in strain: cv. Acebuche
Natural variant19in strain: cv. Bella de Espana; variant 2
Natural variant19in strain: cv. Arbequina; variant 2 and cv. Bella de Espana; variant 1
Natural variant19in strain: cv. Bella de Espana; variant 3
Natural variant19in strain: cv. Acebuche
Natural variant20in strain: cv. Acebuche and cv. Bella de Espana; variant 3
Natural variant20in strain: cv. Bella de Espana; variant 1
Natural variant21in strain: cv. Bella de Espana; variant 3
Natural variant21in strain: cv. Acebuche
Natural variant23in strain: cv. Bella de Espana; variant 2
Natural variant23
Natural variant24in strain: cv. Rowghani; variant 3. In Ole e 1.0105
Natural variant24in Ole e I.4
Natural variant25in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Rowghani; variants 3 and 4. In Ole e 1.0105, Ole e I.3 and Ole e I.4
Mutagenesis2670% loss of IgG binding.
Natural variant28in strain: cv. Zard; variant 2; 50% loss of IgG binding
Mutagenesis29Loss of IgG binding.
Natural variant30in Ole e I.4
Mutagenesis3050% loss of IgG binding.
Mutagenesis32Loss of IgG binding.
Mutagenesis33Loss of IgG binding.
Mutagenesis3450% loss of IgG binding.
Natural variant35in strain: cv. Zard; variant 2
Natural variant38in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca and cv. Zard; variant 2. In Ole e I.4
Natural variant39in strain: cv. Arbequina; variants 1 and 2, cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine, cv. Picual; variants 1 and 2, cv. Rowghani; variants 2, 3 and 4 and cv. Zard; variants 1 and 2. In Ole e 1.0102, Ole e 1.0103, Ole e 1.0105, Ole e I.3 and Ole e I.4
Natural variant44in strain: cv. Rowghani; variants 2, 3 and 4 and cv. Zard; variants 1 and 2. In Ole e 1.0105
Natural variant45in strain: cv. Zard; variant 1 and cv. Rowghani; variants 2 and 3. In Ole e 1.0105
Natural variant46in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca and cv. Rowghani; variant 4. In Ole e I.3 and Ole e I.4
Natural variant46
Natural variant46in strain: cv. Arbequina; variants 1 and 2
Natural variant46in strain: cv. Zard; variant 2
Natural variant47in strain: cv. Rowghani; variant 2 and cv. Zard; variants 1 and 2
Natural variant48in strain: cv. Zard; variant 2
Mutagenesis4950% loss of IgG binding.
Natural variant50in Ole e I.4
Natural variant50in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca and cv. Zard; variant 2
Natural variant50in strain: cv. Rowghani; variant 4. In Ole e I.3
Mutagenesis5060% loss of IgG binding.
Natural variant51in strain: cv. Arbequina; variants 1 and 2, cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine, cv. Picual; variants 1 and 2, cv. Rowghani, variants 2, 3 and 4 and cv. Zard; variants 1 and 2. In Ole e 1.0105, Ole e I.3 and Ole e I.4
Mutagenesis5150% loss of IgG binding.
Mutagenesis55Loss of IgG binding.
Natural variant56in strain: cv. Rowghani; variant 3. In Ole e 1.0102, 1.0103 and 1.0105
Mutagenesis56Loss of IgG binding.
Mutagenesis57Loss of IgG binding.
Natural variant58in strain: cv. Rowghani; variant 4
Mutagenesis58Loss of IgG binding.
Mutagenesis59Loss of IgG binding.
Mutagenesis6060% loss of IgG binding.
Mutagenesis6570% loss of IgG binding.
Mutagenesis6750% loss of IgG binding.
Natural variant69in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4
Mutagenesis70Loss of IgG binding.
Natural variant75in strain: cv. Rowghani; variant 4. In Ole e I.3
Natural variant80in strain: cv. Zard; variant 2
Natural variant81in strain: cv. Zard; variant 2
Natural variant82in strain: cv. Zard; variant 2
Natural variant83in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Zard; variant 2. In Ole e I.4
Natural variant86in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4
Natural variant87
Natural variant91in strain: cv. Arbequina; variants 1 and 2, cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Loaime, cv. Picual; variants 1 and 2, cv. Rowghani; variants 3 and 4 and cv. Zard; variant 2. In Ole e 1.0105, Ole e I.3 and Ole e I.4
Natural variant95in strain: cv. Rowghani; variant 3 and cv. Zard; variant 2. In Ole e 1.0105
Natural variant95in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Rowghani; variant 4. In Ole e I.3
Natural variant99in strain: cv. Acebuche, cv. Arbequina; variants 1 and 2, cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Picual; variant 3, cv. Rowghani; variants 1 and 4 and cv. Zard; variant 2. In Ole e I.2, Ole e I.3 and Ole e I.4
Natural variant100in strain: cv. Zard; variant 2
Natural variant103in Ole e I.4
Natural variant104in strain: cv. Zard; variant 2
Natural variant106in strain: cv. Acebuche, cv. Arbequina; variant 1 and 2, cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine, cv. Picual; variants 1, 2 and 3, cv. Rowghani; variants 1, 2 and 3 and cv. Zard; variant 1. In Ole e 1.0102, Ole e 1.0103, Ole e 1.0105, Ole e I.2 and Ole e I.4
Natural variant106in strain: cv. Zard; variant 2
Natural variant106in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Rowghani; variant 4. In Ole e I.3
Mutagenesis107Loss of IgG binding.
Natural variant108in Ole e 1.0103
Mutagenesis108Loss of IgG binding.
Mutagenesis109Loss of IgG binding.
Mutagenesis110Loss of IgG binding.
Natural variant111
Mutagenesis112Loss of IgG binding.
Natural variant115in strain: cv. Zard; variant 2
Natural variant117in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Rowghani; variant 2 and cv. Zard; variants 1 and 2. In Ole e I.3 and Ole e I.4
Natural variant118in strain: cv. Zard; variant 2
Mutagenesis11970% loss of IgG binding.
Mutagenesis120Loss of IgG binding.
Natural variant121in Ole e 1.0102
Natural variant123in strain: cv. Zard; variant 1 and cv. Rowghani; variant 2. In Ole e 1.0102 and Ole e 1.0103
Mutagenesis123Loss of IgG binding.
Natural variant125in strain: cv. Zard; variant 2
Mutagenesis12580% loss of IgG binding.
Natural variant126in strain: cv. Zard; variant 2
Natural variant132in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4
Mutagenesis13350% loss of IgG binding and 40% loss if IgE binding.
Mutagenesis13430% loss of IgG binding and 50% loss if IgE binding.
Natural variant135in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4
Mutagenesis135No loss of IgG binding and 40% loss if IgE binding.
Mutagenesis13640% loss of IgG binding and 60% loss if IgE binding.
Mutagenesis136-145Decreased IgE binding.
Mutagenesis13720% loss of IgG binding and 80% loss if IgE binding.
Mutagenesis13870% loss of IgG binding and 90% loss if IgE binding.
Natural variant139in strain: cv. Rowghani; variant 2
Mutagenesis13930% loss of IgG binding and 90% loss if IgE binding.
Mutagenesis14050% loss of IgG binding and 50% loss if IgE binding.
Mutagenesis14190% loss of IgG binding and 95% loss if IgE binding.
Mutagenesis141-145Decreased IgE binding.
Mutagenesis14220% loss of IgG binding and 95% loss if IgE binding.
Natural variant144in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2
Natural variant144in strain: cv. Picual; variant 3
Natural variant145in strain: cv. Acebuche
Natural variant145in strain: cv. Zard; variant 2
Natural variant145in strain: cv. Picual; variant 3

Variants

We now provide the "Disease & Variants" viewer in its own tab.

The viewer provides 88 variants from UniProt as well as other sources including ClinVar and dbSNP.

Go to variant viewer

Keywords

Protein family/group databases

PTM/Processing

Features

Showing features for chain, disulfide bond, glycosylation.

TypeIDPosition(s)Description
ChainPRO_00002151131-145Major pollen allergen Ole e 1
Disulfide bond19↔90
Disulfide bond22↔131
Disulfide bond43↔78
Glycosylation111N-linked (GlcNAc...) (complex) asparagine; alternate
Glycosylation111N-linked (GlcNAc...) (high mannose) asparagine; alternate

Post-translational modification

N-glycosylated; contains high mannose (Man7-GlcNAc) and partially fucosylated complex glycans (GlcNAc-Man3-Xyl-GlcNAc). Complex glycans may contribute to the antigenicity. Exists both in a glycosylated and in a non-glycosylated form. Ole e 1 and Ole e 1.0103 are the only non-glycosylated isoallergens.
A second potential glycosylation site exists at position 50 in cv. Bella de Espana and cv. Hojiblanca.

Keywords

PTM databases

Expression

Tissue specificity

Expressed in tapetum and pollen grains. Not detected in petals, roots or leaves.

Developmental stage

Expressed at late stages of pollen development. Up-regulated during pollen germination and pollen tube growth.

Structure

Family & Domains

Domain

Regions 91-102 and 109-130 are immunodominant T-cell epitopes. Mutations in the C-terminus (135-145) reduce allergenic activity but do not change the ability to stimulate allergen-specific T-cells.

Sequence similarities

Belongs to the Ole e I family.

Family and domain databases

Sequence

  • Sequence status
    Complete
  • Length
    145
  • Mass (Da)
    16,330
  • Last updated
    1993-10-01 v2
  • Checksum
    3F11F04E01C12C84
EDIPQPPVSQFHIQGQVYCDTCRAGFITELSEFIPGASLRLQCKDKENGDVTFTEVGYTRAEGLYSMLVERDHKNEFCEITLISSGRKDCNEIPTEGWAKPSLKFKLNTVNGTTRTVNPLGFFKKEALPKCAQVYNKLGMYPPNM

Sequence caution

The sequence CAA73036.1 differs from that shown. Reason: Erroneous initiation
The sequence CAA73037.1 differs from that shown. Reason: Erroneous initiation
The sequence CAA73038.1 differs from that shown. Reason: Erroneous initiation

Polymorphism

Several isoforms of the allergen exist due to polymorphism.

Keywords

Sequence databases

Nucleotide SequenceProtein SequenceMolecule TypeStatus
Y12426
EMBL· GenBank· DDBJ
CAA73036.1
EMBL· GenBank· DDBJ
mRNA Different initiation
Y12427
EMBL· GenBank· DDBJ
CAA73037.1
EMBL· GenBank· DDBJ
mRNA Different initiation
Y12428
EMBL· GenBank· DDBJ
CAA73038.1
EMBL· GenBank· DDBJ
mRNA Different initiation
AF500908
EMBL· GenBank· DDBJ
AAQ07442.1
EMBL· GenBank· DDBJ
mRNA
AF515277
EMBL· GenBank· DDBJ
AAQ08186.1
EMBL· GenBank· DDBJ
mRNA
AF515278
EMBL· GenBank· DDBJ
AAQ08187.1
EMBL· GenBank· DDBJ
mRNA
AF515279
EMBL· GenBank· DDBJ
AAQ08188.1
EMBL· GenBank· DDBJ
mRNA
AF515280
EMBL· GenBank· DDBJ
AAQ08189.1
EMBL· GenBank· DDBJ
mRNA
AF515281
EMBL· GenBank· DDBJ
AAQ08190.1
EMBL· GenBank· DDBJ
mRNA
AF532753
EMBL· GenBank· DDBJ
AAQ10267.1
EMBL· GenBank· DDBJ
mRNA
AF532754
EMBL· GenBank· DDBJ
AAQ10268.1
EMBL· GenBank· DDBJ
mRNA
AF532755
EMBL· GenBank· DDBJ
AAQ10269.1
EMBL· GenBank· DDBJ
mRNA
AF532756
EMBL· GenBank· DDBJ
AAQ10270.1
EMBL· GenBank· DDBJ
mRNA
AF532757
EMBL· GenBank· DDBJ
AAQ10271.1
EMBL· GenBank· DDBJ
mRNA
AF532758
EMBL· GenBank· DDBJ
AAQ10272.1
EMBL· GenBank· DDBJ
mRNA
AF532759
EMBL· GenBank· DDBJ
AAQ10273.1
EMBL· GenBank· DDBJ
mRNA
AF532760
EMBL· GenBank· DDBJ
AAQ10274.1
EMBL· GenBank· DDBJ
mRNA
AF532761
EMBL· GenBank· DDBJ
AAQ10275.1
EMBL· GenBank· DDBJ
mRNA
AF532762
EMBL· GenBank· DDBJ
AAQ10276.1
EMBL· GenBank· DDBJ
mRNA
AF532763
EMBL· GenBank· DDBJ
AAQ10277.1
EMBL· GenBank· DDBJ
mRNA
AF532764
EMBL· GenBank· DDBJ
AAQ10278.1
EMBL· GenBank· DDBJ
mRNA
AF532765
EMBL· GenBank· DDBJ
AAQ10279.1
EMBL· GenBank· DDBJ
mRNA
AF532766
EMBL· GenBank· DDBJ
AAQ10280.1
EMBL· GenBank· DDBJ
mRNA
AF532767
EMBL· GenBank· DDBJ
AAQ10281.1
EMBL· GenBank· DDBJ
mRNA
AY137467
EMBL· GenBank· DDBJ
AAN18042.1
EMBL· GenBank· DDBJ
mRNA
AY137468
EMBL· GenBank· DDBJ
AAN18043.1
EMBL· GenBank· DDBJ
mRNA
AY137469
EMBL· GenBank· DDBJ
AAN18044.1
EMBL· GenBank· DDBJ
mRNA
AY159880
EMBL· GenBank· DDBJ
AAO22132.1
EMBL· GenBank· DDBJ
Genomic DNA
AY159881
EMBL· GenBank· DDBJ
AAO22133.1
EMBL· GenBank· DDBJ
Genomic DNA
EF541386
EMBL· GenBank· DDBJ
ABP58632.1
EMBL· GenBank· DDBJ
mRNA
EF541387
EMBL· GenBank· DDBJ
ABP58633.1
EMBL· GenBank· DDBJ
mRNA
EF541388
EMBL· GenBank· DDBJ
ABP58634.1
EMBL· GenBank· DDBJ
mRNA
EF541389
EMBL· GenBank· DDBJ
ABP58635.1
EMBL· GenBank· DDBJ
mRNA
EF541390
EMBL· GenBank· DDBJ
ABP58636.1
EMBL· GenBank· DDBJ
mRNA
EF541391
EMBL· GenBank· DDBJ
ABP58637.1
EMBL· GenBank· DDBJ
mRNA
S75766
EMBL· GenBank· DDBJ
AAB32652.2
EMBL· GenBank· DDBJ
mRNA

Similar Proteins

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. Our staff consists of biologists and biochemists that are not trained to give medical advice.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.
FeedbackHelp